drugset / Trial / NCT04357795

Effect of Cequa™ in Subjects With Dry Eye Disease

NCT04357795

Phase 4 Completed 135 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.

Timeline

Start
2020-06-29
Primary completion
2022-06-24
Completion
2022-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.09 % Other

Indications